The vision of Life Science Leader is to help facilitate connections and foster collaborations in pharma and med device development to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute
Issue link: https://lifescienceleadermag.epubxp.com/i/469666
LIFESCIENCELEADER.COM 39 MARCH 2015 is your financial n a c i a s y o u i a n c a s y o r f n l r c s o f n a n a l i s y u r i a n c a y r f n a c i l s y n n a i s y o u f n c a l o u r i a i l r f n l i s y o u f i n a n c s r n a c i a l n s y f a s y o u f i c a l i o u r n a n i a l o i n n c s y o u r n a n i a l i s r f n a n c a c l i y o u n i y o u f i n a n c a l s r f a n y l y o a s o u r f n a n c a l i s f i n n c i a y r i o u n c i s o u r i n a a l s y r f n n c a n i r l y o u f i a c i s o c future wide open f u u r e w d e p e n f t u r w i e o p d f w d p u d e e n u t r e w i o e i e o u t u r w d e o e n t u r e w d o p e u e e f u r e w i d p n f u t u r w d e o p e w i e o f d e o p e u t u r e w d o n i n o f u r w i e p e n f u t u r e w d n o u e d o p e n f u t u r e w e o e o d n w f u t i e u u r e w d e o p e n i d n f u o p e u o ? Looking to reposition an existing product or expand your portfolio with a differentiated product? The 505(b)(2) approval pathway is your best way forward to develop new drugs in a fraction of the time and cost required by traditional pathways. Camargo is the most experienced global strategist specializing in 505(b)(2) and is your go-to for development from concept to commercialization. Go With Camargo. Call (888) 451-5708 Email services@camargopharma.com Follow blog.camargopharma.com Visit camargopharma.com Visit us at DCAT Week 2015 - Suite 1802 The Lexington NYC Hotel READY TO IDENTIFY AND DEVELOP A VIABLE PRODUCT? and the fact that his staff would be disappointed that he wasn't travelling more. Upon the "bombshell" announcement that he was sick, the company's stock stayed steady. PERSONAL EXPERIENCE WITH ILLNESS CAN BE HARNESSED TO PRODUCTIVE ENDS Additionally, personal experience with serious illness can not only allow biotech executives to shape their own company positively, but also allow them to serve as thought leaders for the field as a whole. For example, Neil Fowler, CEO of the small biotech Liquidia, was diagnosed with a tonsil tumor and was successfully treated. He used this experience to pub- licly voice his support for the wider development of Gardasil, a human papilloma virus vaccine that some believe might prevent the form of cancer he had from ever developing. A serious illness can even spur a biotech executive to discern shortcomings in the healthcare system and work to address those issues. Consider Myrtle Potter. She had already success- fully served as president and COO at Genentech, president at Bristol-Meyers Squibb, and vice president at Merck, when one night in 2005 she began slipping into a coma at home. Rushed to the hospital, she ended up with a failing liver and lungs as well as total kidney failure. Toxins flooded her body, and she lost close to 30 pounds, more than half her hair and even some skin. She spent a year recovering from what turned out to be a severe allergic reaction to a medication. Harnessing this experience, Potter started two com- panies to help deal with gaps in healthcare — Myrtle Potter & Co., a B2B healthcare company, and Myrtle Potter Media Inc., a company that helps consum- ers navigate the U.S. healthcare system. She has estab- lished herself as a healthcare expert through her online content and media appearances, providing patients with practical information from how to get the right insurance to how to have a dialogue with their doctors. Now, that's turning a near-tragic outcome into a productive result. Conversely, keeping your past health challenges a secret only runs the risk of having an intrepid reporter dig for the facts and spill the beans publicly — which won't be good for your reputation or, potentially, your company's bottom line. Even though Apple remained an industry leader through the period of illness and untimely death of Steve Jobs, the secrecy and obfuscation surrounding his cancer was criticized by numerous industry and media observers. Many ailing execu- tives might be tempted to resist divulging a serious illness because they fear a loss of power, but current and potential investors have the right to know what's going on. A biotech executive's personal experience with health issues isn't always completely negative. Instead, they can harness these experiences to make a company stronger. L